Aimmune Therapeutics
AIMT
AIMT was delisted on the 12th of October, 2020.
58 hedge funds and large institutions have $551M invested in Aimmune Therapeutics in 2015 Q3 according to their latest regulatory filings, with 58 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$142M |
| 2 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
+$95.6M |
| 3 |
AC
Aisling Capital
New York
|
+$65.9M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$29M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$23.3M |
Top Sellers
AIMT Hedge Fund Activity: Q3 2015 in Review
58 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Aimmune Therapeutics (AIMT) for Q3 2015, worth a combined $551M.
Buyers outnumbered sellers: 58 funds opened new AIMT positions and 0 closed out — a net gain of 58 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $142M.
- 58 institutional investors held Aimmune Therapeutics (AIMT) as of Q3 2015, up from 0 in Q2 2015.
- Funds reported $551M of Aimmune Therapeutics stock for Q3 2015.
- 58 funds opened new Aimmune Therapeutics positions in Q3 2015 and 0 closed out, a net change of +58 holders.
- The largest Aimmune Therapeutics buyer in Q3 2015 was Fidelity Investments, an estimated $142M added.
Based on aggregated 13F filings for Q3 2015.